Layered uncertainties make this case an unusually difficult case in which to predict the outcome
On April 15, the Supreme Court will hear oral argument in Association for Molecular Pathology v. Myriad Genetics, a case that could answer the question, “Under what conditions, if any, are isolated human genes patentable?” Kevin Emerson Collins, JD, patent law expert and professor of law at Washington University in St. Louis, believes that layered uncertainties make this case an unusually difficult case in which to predict the outcome.
During the early 1990s, Myriad Genetics made important scientific discoveries related to mutations in the BRCA 1 and BRCA 2 genes, which are biomarkers for increased risk of breast and ovarian cancer. Based on this work, Myriad sought, and obtained, patent protection for “isolated” DNA molecules that embody these sequences.
The Supreme Court’s opinion in Myriad will determine whether Myriad’s gene patents are valid or, alternatively, whether they were improperly issued from the beginning.
“The legal controversy centers on patent law’s ‘products of nature’ doctrine—a doctrine that prevents the patenting of newly made products that do not display a ‘marked difference’ from naturally occurring products,” Collins says.
“A perfectly circular section cut out of a leaf of a newly discovered plant may be technically new at the time that it is first made – and it may be socially useful if the leaf contains chemicals that are natural wound healers, but it’s likely an unpatentable product of nature because there is no marked difference between the newly created product and the naturally occurring product.
“Importantly, the Myriad gene patents only encompass DNA molecules in an ‘isolated’ state, separate from the remainder of the chromosome in which they exist in a human body, and they thus describe molecules that were technically new when Myriad first made them.”
The question before the Court is whether the structural and functional differences between naturally occurring DNA molecules and DNA molecules in an isolated state is sufficiently significant to constitute a “marked difference” and to sanction the patenting of the isolated DNAs.
Behind the legal controversy is an economic controversy that may (or may not) influence the Supreme Court’s pronouncement on the products of nature doctrine. “The social costs of the exclusive rights to inventions granted by patents are normally justified by the incentives that patents provide for self-interested entities to invest in research and development and generate the socially valuable inventions,” Collins says.
However, under some circumstances, there are legitimate concerns that the incentive-based benefits of patents may not outweigh these costs.
“One function of the products of nature doctrine is to ensure that the basic tools of scientific and technological work are not constrained by claims of patent rights and remain free for all to use as inputs into future research,” says Collins.
“To the extent that isolated genes are essential technological and scientific building blocks, the costs of Myriad’s gene patents in the form of slower innovation in the future may be so great that they will outweigh the benefits of the patent-induced incentives that speed up the creation of the isolated genes themselves.”
The Latest Bing News on:
Are human genes patentable
- The Origins of Covid-19 Are More Complicated Than Once Thoughton August 4, 2022 at 4:00 am
Scientists used painstaking research, genomics, and clever statistics to definitively track two distinct strains of the virus back to a wet market in Wuhan.
- U.S. Senate bill would reform patent-eligibility standardson August 3, 2022 at 7:22 am
U.S. Republican Senator Thom Tillis of North Carolina said Wednesday that he has introduced a bill to address the divisive issue of what can be patented.
- Q&A – Indian Patent Law On Pharmaceuticals.on July 28, 2022 at 7:58 pm
Special 301 report of the U.S. Trade Representative retained India on its Priority Watch List and in respect of patents, the report says that they “continued to monitor the restriction on ...
- Genetic Recombination Appears to be Common in the Human Genomeon July 25, 2022 at 3:54 pm
When the genomes of parents come together to create the genome of a child, their DNA recombines; similar parts are rearranged so that a child carries secti | Genetics And Genomics ...
- Patenting life?on July 18, 2022 at 6:35 am
or changing the germ line genetic identity of a human or animal are also not patentable (Rule 28 (1) EPC). As regards the human body, Rule 29 EPC states that its various stages of formation and ...
- Uncharted genetic territory offers insight into human-specific proteinson July 13, 2022 at 6:38 pm
An international research consortium brings together 7,200 segments of the human genome that are virtually unexplored and presents a roadmap for integrating them into human genome databases. Much of ...
- US Supreme Court rules DNA is not patentable, but synthetically created yeson July 13, 2022 at 5:00 pm
The court has said that laws of nature, natural phenomena and abstract ideas are not patentable ... Office has been awarding patents on human genes for almost 30 years, but opponents of ...
- Relax rights to human geneson January 30, 2019 at 1:16 pm
As unbelievable as it may sound, approximately 20% of the human genome is under ... the DNA that constitutes a gene or a mutation therein is actually patentable. Originally intended to provide ...
- How human genes become patentedon May 13, 2009 at 5:00 am
Now, patents on human genes must specify a new use ... about why this kind of thing isn't really something that should be patentable are really strong at a theoretical level," she said.
- ACLU sues over patents on breast cancer geneson May 12, 2009 at 5:00 am
The lawsuit also challenges genetic patenting in general, noting that about 20 percent of all human genes are patented ... that doesn't make the eyeball patentable. "Now if they create another ...
The Latest Google Headlines on:
Are human genes patentable
The Latest Bing News on:
- Cellex drops patent case over Siemens COVID-19 testson August 5, 2022 at 1:23 pm
North Carolina biotech company Cellex Inc has dropped a patent lawsuit against Siemens Healthineers AG over the design of its rapid COVID-19 self-tests less than a week after bringing the case in ...
- BriaCell signs exclusive licensing deal with UMBC for cancer treatment candidateon August 5, 2022 at 11:41 am
BriaCell Therapeutics, one of the first tenants at B.Labs in Cira Centre, has negotiated a deal for an exclusive license for an experimental cancer therapy.
- A Cautious Welcome: Patent Community Chimes in on Tillis’ Eligibility Billon August 4, 2022 at 9:28 am
Senator Thom Tillis (R-NC) introduced the Patent Eligibility Restoration Act of 2022, S.4734, which would amend the U.S. Patent Act to clarify the application of 35 U.S.C. Section 101 to certain ...
- Most Contentious Issue: Tillis Takes Another Stab at Rewriting Patent Eligibility Lawon August 3, 2022 at 4:18 pm
A former PTO director and a former Federal Circuit judge hailed the legislation as providing clarity and predictability in a contentions area of law. An attorney for a tech industry trade group warned ...
- Cibus Expands Its Extensive Patent Portfolio for Agricultural Crop Traitson August 3, 2022 at 9:15 am
PSR is called a Productivity Trait because it is part of a class of agricultural traits that address productivity and sustainability in farming by improving crop yields and lowering costs like diesel, ...
- 'What’s wrong with having lots of patents?' Federal appeals judge sides with AbbVie in Humira caseon August 2, 2022 at 11:55 am
A federal appeals court ruled in AbbVie’s favor on Monday, upholding an Illinois court’s decision to dismiss allegations that the pharma giant created an unlawful “patent thicket” around its ...
- SNIPR Biome announces new patent granted for applications targeting E. coli infectionson August 2, 2022 at 3:39 am
SNIPR Biome has today (August 2) announced that it has been granted a patent for bacteriophage cocktail targeting E.coli infections.
- SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phageon August 1, 2022 at 11:03 pm
SNIPR Biome ApS (or “the Company”), a clinical-stage biotechnology company developing CRISPR-based precision medicines, announces today the grant of patent number US11,400,110 by the US Patent and ...
- Bausch Health asserts push to 'vigorously' defend Xifaxan patent litigationon August 1, 2022 at 10:39 am
Bausch Health will continue litigating over its Xifaxan drug, threatening to appeal all the way up to the US Court of Appeals for the Federal Circuit. The Quebec-based company, through its ...
- Siemens sued for patent infringement over COVID-19 test designon August 1, 2022 at 10:01 am
North Carolina biotech company Cellex Inc sued Siemens Healthineers AG in Delaware federal court on Friday, alleging Siemens' COVID-19 rapid self-tests violate a patent covering a Cellex design.